GEMCITABINE HYDROCHLORIDE

AU:D L01BC05(WHO) AU:S4(Prescription only)CA:℞-onlyUK:POM(Prescription only)US:℞-onlyIn general: ℞ (Prescription only) 4-Amino-1-(2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl)pyrimidin-2(1H)-on 95058-81-4Y 60750 4793 DB00441Y 54753Y B76N6SBZ8R D02368Y CHEBI:175901Y ChEMBL888Y DTXSID3040487 Interactive image c1cn(c(=O)nc1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1YKey:SDUQYLNIPVEER‍‍‍‍‍‍​​​‍​​​​​​B-QPPQHZFASA-NY Gemcitabine, sold under the brand nameGemzar, among others,is achemotherapy medicationused to treatcancers.It is used to treattesticular cancer,breast cancer,ovarian cancer,non-small cell lung cancer,pancreatic cancer, andbladder cancer.It is administered byintravenous infusion.It acts against neoplastic growth, and it inhibits the replication ofOrthohepevirus A, the causative agent ofhepatitis E, through upregulation ofinterferonsignaling. Common side effects includebone marrow suppression, liver and kidney problems,nausea,fever,rash,shortness of breath, mouth sores,diarrhea, neuropathy, andhair loss.Use duringpregnancywill likely result infetalharm.Gemcitabine is in thenucleoside analogfamily of medication.It works by blocking the creation of newDNA, which results in cell death. Gemcitabine was patented in 1983 and was approved for medical use in 1995.Generic versions were introduced in Europe in 2009 and in the US in 2010.It is on theWHO Model List of Essential Medicines.